Phoenix Biotech (NASDAQ:PBAX) announced in an 8-K that it has postponed its extension vote from July 5 to 11 am ET July 7.
The SPAC’s existing transaction deadline falls on the following day, July 8, but its extension proposal would allow the Phoenix Biotech to extend this by one month up to six times for $0.03 per share contributions to its trust.
This is a boost up from the $0.025 per share Phoenix Biotech had pledged to contribute in its previous proxy. The SPAC now plans to use the extra time to solicit redemption reversals from shareholders, and its sponsor has also converted 4,596,250 Class A shares it holds into Class B shares.
Going into the vote, Phoenix Biotech has about $13.3 million in its trust after seeing 92.6% of shares redeemed at an earlier meeting.
It announced a $112 million combination with CERo Therapeutics last month having terminated an earlier deal with Intrinsic Medicine. San Francisco-based CERo is developing a line of potential cancer treatments and expects to file its first investigational new drug (IND) application in 2024.
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...
M3-Brigade V (NASDAQ:MBAV) has entered into a definitive agreement to combine with crypto treasury firm ReserveOne, assembling about $1 billion in equity funding. ReserveOne is setting up a diversified Bitcoin and digital asset treasury with a portion of its investments going towards blockchain infrastructure and venture raises. The combined company is expected to trade on...
At the SPAC of Dawn As the SPAC market has warmed in 2025, only 21 of the 70 SPACs (30%) that have IPO’d thus far have overfunded their trusts to draw in investors and none of these funded to more than 101%. By contrast, 87% of 2023 SPACs were overfunded – some to as high...
Emmis Acquisition Corporation (NASDAQ:EMISU) has filed for a $100 million SPAC to take a look at the manufacturing sector after a few unique wrinkles in their IPO process. Initial investors are set to receive one right to a 1/10 share in each unit purchased and the SPAC will have 18 months to complete a business...
Chenghe III (NASDAQ:CHEC.U) has filed for a $110 million SPAC to continue the team’s growing series while turning to a new underwriter. The new SPAC is offering investors a 1/2 warrant in each unit and no overfunding of the trust, but it will need to complete a business combination within 18 months of its IPO...